Krystal Biotech (KRYS)

Executive Summary

Krystal Biotech is a gene therapy company leveraging its proprietary HSV-1-based platform to develop treatments for genetic and rare diseases. The company's first commercial product, Vyjuvek (beremagene geperpavec), is approved for dystrophic epidermolysis bullosa (DEB), generating revenue and validating the platform. Beyond DEB, Krystal has a broad pipeline targeting cystic fibrosis (KB407), alpha-1 antitrypsin deficiency (KB408), cancer (KB707), neurotrophic keratitis (KB801), and aesthetic indications (KB301). Recently, the company initiated a Phase 3 trial for KB803, a next-generation DEB therapy, and continues to advance multiple Phase 1/2 studies. With a strong cash position and a validated delivery platform, Krystal is well-positioned to expand into new indications and potentially achieve multiple regulatory milestones. Key near-term catalysts include data readouts from KB803, KB407, and KB707, which could drive significant upside.

Upcoming Catalysts (preview)

• H1 2027Phase 3 KB803 data for dystrophic epidermolysis bullosa80% success
• H2 2026Phase 1/2 KB707 (HSV-based IL-12) melanoma data60% success
• 2027Phase 1/2 KB801 data for neurotrophic keratitis65% success